American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients
Issued Date
2022-09-13
Resource Type
ISSN
24739529
eISSN
24739537
Scopus ID
2-s2.0-85134041161
Pubmed ID
35503027
Journal Title
Blood Advances
Volume
6
Issue
17
Start Page
4915
End Page
4923
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Advances Vol.6 No.17 (2022) , 4915-4923
Suggested Citation
Cuker A., Tseng E.K., Nieuwlaat R., Angchaisuksiri P., Blair C., Dane K., DeSancho M.T., Diuguid D., Griffin D.O., Kahn S.R., Klok F.A., Lee A.I., Neumann I., Pai A., Righini M., Sanfilippo K.M., Siegal D.M., Skara M., Terrell D.R., Touri K., Akl E.A., Al Jabiri R., Al Jabiri Y., Barbara A.M., Bognanni A., Boulos M., Brignardello-Petersen R., Charide R., Colunga-Lozano L.E., Dearness K., Darzi A.J., Hussein H., Karam S.G., Mansour R., Morgano G.P., Morsi R.Z., Muti-Schunemann G., Nadim M.K., Philip B.A., Qiu Y., Benitez Y.R., Stevens A., Solo K., Wiercioch W., Mustafa R.A., Schunemann H.J. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances Vol.6 No.17 (2022) , 4915-4923. 4923. doi:10.1182/bloodadvances.2022007561 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87242
Title
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients
Author(s)
Cuker A.
Tseng E.K.
Nieuwlaat R.
Angchaisuksiri P.
Blair C.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Kahn S.R.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Siegal D.M.
Skara M.
Terrell D.R.
Touri K.
Akl E.A.
Al Jabiri R.
Al Jabiri Y.
Barbara A.M.
Bognanni A.
Boulos M.
Brignardello-Petersen R.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Hussein H.
Karam S.G.
Mansour R.
Morgano G.P.
Morsi R.Z.
Muti-Schunemann G.
Nadim M.K.
Philip B.A.
Qiu Y.
Benitez Y.R.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Schunemann H.J.
Tseng E.K.
Nieuwlaat R.
Angchaisuksiri P.
Blair C.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Kahn S.R.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Siegal D.M.
Skara M.
Terrell D.R.
Touri K.
Akl E.A.
Al Jabiri R.
Al Jabiri Y.
Barbara A.M.
Bognanni A.
Boulos M.
Brignardello-Petersen R.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Hussein H.
Karam S.G.
Mansour R.
Morgano G.P.
Morsi R.Z.
Muti-Schunemann G.
Nadim M.K.
Philip B.A.
Qiu Y.
Benitez Y.R.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Schunemann H.J.
Author's Affiliation
Faculty of Dentistry
Ramathibodi Hospital
L’École de médecine
School of Medicine
American University of Beirut
The University of Jordan
King Hussein Cancer Center
McMaster University
University of Oklahoma Health Sciences Center
Pontificia Universidad Católica de Chile
The University of Chicago
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
Saint Michael's Hospital University of Toronto
Leids Universitair Medisch Centrum
Faculty of Medicine - Ain Shams University
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Lincoln Medical and Mental Health Center
The Johns Hopkins Hospital
Research and Development at United Health Group
Prohealth NY
Ramathibodi Hospital
L’École de médecine
School of Medicine
American University of Beirut
The University of Jordan
King Hussein Cancer Center
McMaster University
University of Oklahoma Health Sciences Center
Pontificia Universidad Católica de Chile
The University of Chicago
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
Saint Michael's Hospital University of Toronto
Leids Universitair Medisch Centrum
Faculty of Medicine - Ain Shams University
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Lincoln Medical and Mental Health Center
The Johns Hopkins Hospital
Research and Development at United Health Group
Prohealth NY
Other Contributor(s)
Abstract
Background: COVID-19–related acute illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19. Methods: ASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines. Results: The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19–related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants. Conclusion: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19–related acute illness.